|

NST-6179 Part A Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • NorthSea Therapeutics B.V.1

Indications

  • Intestinal Failure-associated Liver Disease1
  • Liver Disease1

Scottsdale, Arizona1 trial

A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).

Mayo Clinic Scottsdale Campus

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.